Status:
UNKNOWN
Skipping BCG for T1a Urinary Bladder Tumor.
Lead Sponsor:
Assiut University
Conditions:
Superficial Bladder Cancer t1a
Eligibility:
All Genders
Brief Summary
Bladder cancer is the most common malignancy involving theurinary system and the ninth most common malignancy worldwide .In Egypt, the urinary bladder cancer accounted for about 31% of the total incid...
Detailed Description
Bladder cancer is the most common malignancy involving theurinary system and the ninth most common malignancy worldwide .In Egypt, the urinary bladder cancer accounted for about 31% of the total incid...
Eligibility Criteria
Inclusion
- The study will include all patients that diagnosed for the first time as T1a urothelial carcinoma .
Exclusion
- Other variants of bladder cancer as squamous cell carcinoma of urinary bladder ,small cell carcinoma of urinary bladder, -sarcomatoid variant of urinary bladder \& anaplastic cell carcinoma of urinary bladder
- patients Who were previously treated for bladder cancer by any modality including TURT, BCG, chemotherapy and radiotherapy
Key Trial Info
Start Date :
March 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 4 2022
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04298073
Start Date
March 4 2020
End Date
April 4 2022
Last Update
March 6 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.